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Abstract
Hydrogen sulphide (H2S) is an emerging molecule in many cardiovascular complications
but its role in left ventricular hypertrophy (LVH) is unknown. The present study explored the
effect of exogenous H2S administration in the regression of LVH by modulating oxidative
stress, arterial stiffness and expression of cystathione γ lyase (CSE) in the myocardium.
Animals were divided into four groups: Control, LVH, Control-H2S and LVH-H2S. LVH was
induced by administering isoprenaline (5mg/kg, every 72 hours, S/C) and caffeine in drink-
ing water (62mg/L) for 2 weeks. Intraperitoneal NaHS, 56μM/kg/day for 5 weeks, was given
as an H2S donor. Myocardial expression of Cystathione γ lyase (CSE) mRNA was quanti-
fied using real time polymerase chain reaction (qPCR).There was a 3 fold reduction in the
expression of myocardial CSE mRNA in LVH but it was up regulated by 7 and 4 fold in the
Control-H2S and LVH-H2S myocardium, respectively. Systolic blood pressure, mean arte-
rial pressure, pulse wave velocity were reduced (all P<0.05) in LVH-H2S when compared to
the LVH group. Heart, LV weight, myocardial thickness were reduced while LV internal
diameter was increased (all P<0.05) in the LVH-H2S when compared to the LVH group.
Exogenous administration of H2S in LVH increased superoxide dismutase, glutathione and
total antioxidant capacity but significantly reduced (all P<0.05) plasma malanodialdehyde in
the LVH-H2S compared to the LVH group. The renal cortical blood perfusion increased by
40% in LVH-H2S as compared to the LVH group. Exogenous administration of H2S sup-
pressed the progression of LVH which was associated with an up regulation of myocardial
CSE mRNA/ H2S and a reduction in pulse wave velocity with a blunting of systemic hemo-
dynamic. This CSE/H2S pathway exhibits an antihypertrophic role by antagonizing the
hypertrophic actions of angiotensin II(Ang II) and noradrenaline (NA) but attenuates oxida-
tive stress and improves pulse wave velocity which helps to suppress LVH. Exogenous
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administration of H2S augmented the reduced renal cortical blood perfusion in the LVH
state.
Introduction
Left ventricular hypertrophy (LVH) is a compensatory response of the heart against the ele-
vated after load to maintain the ejection fraction. Persistent elevated hypertrophy progresses to
dilation of the heart and decreased ejection fraction which leads to heart failure [1]. Frequently,
the manifestation of ventricular hypertrophy is associated with a thickening of the myocar-
dium, fibrosis [2] and altered gene expression[3]. Elevated blood pressure and LVH have been
found to be surrogate markers of each other in many studies [4–6] and spontaneously hyper-
tensive rats (SHR) have been used as model of LVH [7]. It has been reported that lowering
blood pressure following administration of captopril resulted in a regression of LVH[4].
Hydrogen sulphide (H2S) is a well known gaseous transmitter having pleotropic effects on
the cardiovascular system. Studies have shown that H2S can be produced from cystathione γ
lyase(CSE) found predominately in the heart [8], cystathione β synthase (CBS) in mammalian
tissue especially the kidney[9, 10] while 3-mercaptopyruvate sulphur transferase (MST) is
responsible for H2S production in the brain[11]. H2S has been shown to attenuate cardiac
hypertrophy induced by abdominal aortic coaractationin Sprague-Dawley rats [12]. A
decreased concentration of H2S has a possible role in the pathogenesis of hypertension [13].
Hydrogen sulphide (H2S) has been reported to modulate vascular tone [14]and has a cardio
protective role [15]. Oxidative stress is considered to play a major contribution in the patho-
genesis of LV remodelling [16–18]. H2S has an antioxidant role by suppressing NAPH oxidase
[19], scavenging lipid peroxides [20, 21], potentiating catalase and superoxide dismutase while
up regulating GSH [22] in the brain and endothelial cells which may play a therapeutic role in
many diseased conditions where the suppression of oxidative stress is required.
As indicated above, exogenous H2S may be a therapeutic option for cardiovascular diseases
including hypertension and cardiac hypertrophy while based on the recent literature reviews
[23–25], the role of H2S in LVH has not yet been explored. So far what is unknown is the func-
tional contribution of the H2S producing enzyme particularly CSE in LVH and the impact of
up regulation of CSE on the heart following H2S administration on the regression of LVH. A
recent report [26] has demonstrated that selective homocysteine lowering potently attenuates
pressure overload-induced cardiomyopathy via reduced oxidative stress but highlighted the
contribution of the cystathione β synthase (CBS) enzyme in pressure overload cardiac hypertro-
phy and heart failure.
Increased levels of vasoconstrictors, such as Ang II in a fructose fed model of LVH [27] and
NA in isoprenaline/caffeine model have been reported [28–30]. However, the status of these
vasoconstrictors in response to up regulation of the CSE/H2S pathway is unexplored.
Oxidative stress in cardiomyopathy and heart failure has been attributed to the selective
homocysteine lowering which effectively attenuates pressure overload-induced cardiomyopa-
thy via reduced oxidative stress [26]. However, the levels of conventional oxidative stress mark-
ers such as malanodialdehyde (MDA), superoxide dismuatse (SOD), glutathione (GSH) and
total antioxidant capacity (T-AOC) inLVH and the contribution of H2S as antioxidant in the
regression of LVH is also unknown. Increased oxidative stress is related to endothelial dysfunc-
tion while exogenous administration of antioxidants like vitamins C and E have been found
to reduce the endothelial dysfunction by reducing pulse wave velocity and oxidative stress
CSE/H2S in the Myocardium Inhibit the Progression in LVH
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markers in essential hypertensive patients [31]. The present study hypothesized that there is a
down regulation of CSE in the heart with an increased oxidative stress in the systemic circula-
tion in LVH.We also hypothesized that exogenous administration of H2S would up regulate
CSE in the heart by attenuating the LV index, heart index, thickness of myocardium while
attenuating oxidative stress and endothelial dysfunction which would help suppress the pro-
gression of LVH.
Materials and Methods
Animals
Thirty sixWistar-Kyoto rats were obtained from the animal research and service centre
(ARASC) at Universiti Sains Malaysia, Penang, Malaysia with an initial body weight ranging
from 180 to 200g. The rats were acclimatized for 5 days in the transit animal room environ-
ment at the School of Pharmaceutical Sciences, USM and were supplied with food and water
ad libitum. Animals were divided into two main groups; one for the cardiovascular investiga-
tions and the other for the molecular expression study of cardiac cystathione γ lyase (CSE
mRNA). Each group comprised: Control, LVH, Control-H2S and LVH-H2S (n = 6 rats per
group) for the acute studies while same groups for the cardiac CSE mRNAs expression studies
in which each group consists of 3 animals and each animal has triplicate so total number of
replicate were 9 in one group (n = 9). LVH was induced by the administration of 5 subcutane-
ous injections of isoprenaline of 5mg/kg at 72 h intervals with caffeine 62mg/L in the drinking
water for a period of 2 weeks as previously reported [32, 33] but with minor modification as
reported [30]. NaHS (H2S donor) was administered via an intra-peritoneal injection of NaHS
(56μM) at the same time each day for 5 weeks [13]. Blood was collected from the tail vein and
centrifuged at 5000rpm for 10 minutes; plasma was removed and stored at -70°C. After thaw-
ing, samples were taken for measurement of Ang II, NAand antioxidant markers. This protocol
was approved by the Animal Research and Service Centre (ARASC) at Universiti Sains Malay-
sia with the approval number 2012/76/364.
Relative Quantification of CSE mRNA Expression in the Heart of
Control, LVH, Control-H2S and LVH-H2S Rats
Extraction of target tissue from animal. All equipment (scissors, blades, harvesting desk,
beaker, tissue test tubes) was washed with RNAZap1 (Ambion, Life Technologies Corporation,
USA) solution to maintain RNA integrity. Animals were killed by cervical dislocation. Hearts
were harvested and immediately tissues were transferred into RNAlater1 solution (Ambion,
Life Technologies Corporation, USA) at 4°C.
Disruption and homogenization of samples. TRIzole reagent (ambion, Life technologies,
USA) was used to extract Total RNA according to the manufacturer’s guidelines. After the vari-
ous sequential steps of homogenization of heart tissue, washing and elution, total RNA was
extracted, optimized and quantified for purity and yield respectively using a microplate reader
(Bio Tek Instrument. Inc., VT, USA). Total RNA was converted to cDNA using a High Capac-
ity RNA-to-cDNA kit (Applied Biosystems, USA) according to instructions provided by manu-
facturer. Conversion of cDNA was done using particular settings for this procedure of Step
One Plus RT-PCR (Applied Biosystems, Singapore).
TaqMan primers and probes for the CSE gene (Gen Bank accession No. NM_017074.1 and
H2S Rn00567128_m1) were derived from TaqMan
1-Gene Expression assays (Applied Biosys-
tems, USA)[34]. Similarly, TaqMan primers and probes for the β-actingene (Gen Bank acces-
sion No. NM_031144.2 and Rn00667869_m1) were derived from TaqMan1-Gene Expression
CSE/H2S in the Myocardium Inhibit the Progression in LVH
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assays (Applied Biosystems, USA)[35, 36]. Quantitative RT-PCR reactions were carried out on
3 experimental animals of one group (3x4 = 12 animals) while each rat heart sample was fur-
ther analyzed in triplicate. Amplification of the housekeeping enzyme (internal control) β-
actin allowed sample loading and normalization to be determined. The relative quantification
of the target gene CSE and internal control β-actin, was calculated using the comparative CT
(threshold cycle) method with arithmetic formula (2-ΔΔCT) [37].
Measurement of H2S Concentration in Plasma and Myocardium of
Control, LVH, Control-H2S and LVH-H2S Rats
A tail vein blood sample was taken on the final day and centrifuged at 5000rpm for 10 minutes
[30]. The measurement of H2S in the heart tissue was followed as previously reported [38].
Heart tissue (50 mg) was homogenized in 0.5 ml of zinc acetate (1%) and mixed with 0.5 ml of
borate buffer (pH 10.01). After this, a volume of 0.5 ml of N, N-2 dimethyl-p-phenylenedia-
mine (20mM) and 0.5 ml of FeCL3 (300mM) were added to the tissue homogenate. Reaction
tubes were immediately sealed and incubated for 30 minutes with shaking at 37°C. After incu-
bation, all the samples were centrifuged and H2S concentration was measured using the same
procedure as described for plasma H2S measurement method. This method has been used
extensively to measure tissue H2S[13, 38–40].
CSE Activity in Cardiac Tissue of Control, LVH, Control-H2S and
LVH-H2S Groups
Cardiac tissue CSE activity was measured by a method [39, 41]. Briefly describing homogenate
of myocardial tissue was suspended in 50 mmol/L ice cold potassium phosphate buffer (pH
6.8). The reaction mixture consists of 100 mmol/L of potassium phosphate buffer (pH 7.4),
10 mmol/L of L-cysteine, 2 mmol/L of pyridoxal 5-phosphate and 10% w/v of cardiac tissue.
Cryo vial test tubes were used as centre wells and each containing 0.5ml of 1% zinc acetate to
trap the gas. An Erlenmeyer Pyrex flask having volume of 25 ml was used to perform the reac-
tion. Erlenmeyer Pyrex flask containing reaction mixture and centre wells were flushed with
N2 and then sealed with paraffin film. The reaction was started by transferring the reaction
flask from ice to shaking water bath at 37°C. A volume of 0.5 ml of 50% trichloroacetic acid
was added to reaction mixture after incubation at 37°C for 90 minutes to stop the reaction.
Flasks were sealed again and incubated at 37°C for 60 minutes to make sure the complete trap-
ping of H2S released from the reaction mixture. All the content of centre wells were transferred
to test tubes while each test tube containing 3.5 ml of water. Afterward, 0.5 ml of 20 mmol/L of
N, N-2 dimethyl-p-phenylenediamine, sulphate in 7.2 mol/L of HCL was added, soon after fol-
lowed by 0.4 ml of 30 mmol/L of FeCL3 in 1.2 mol/L HCL. Absorbance of the resultant reaction
mixture was taken at 670nm. H2S concentration was measured by using standard curve of H2S
solutions (3.125–100μM).
Measurements of Noradrenaline in the Plasma of Control, LVH, Control-
H2S and LVH-H2S Rats
Plasma NA levels were measured on day 35 as reported [30]. Measurement of plasma NA con-
centration required 50 μL of plasma by processed following the instructions and using ELISA
kit purchased from LaborDiagnostika Nord GmbH & Co. KG, Nordhorn, Germany.
CSE/H2S in the Myocardium Inhibit the Progression in LVH
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Measurements of Angiotensin II in the Plasma of Control, LVH, Control-
H2S and LVH-H2S Rats
Plasma Ang II levels were measured using a kit and following manufacturer’s manual. (Cloud-
Clone Corp. Uscn Life Sciences Inc.). All reagents, samples and standards were prepared.
Thereafter, 50μL of sample was added to each well followed immediately by 50μL of Detection
Reagent A. The samples were well shaken, mixed and then incubated for 1 hour at 37°C. Aspi-
ration and washing was repeated 3 times before 100μL prepared Detection Reagent B were
added. The reaction mixture was incubated for 30 minutes at 37°C followed by 5 repetitions of
aspiration and washing. A volume of 90μL Substrate Solution was added and incubated for 15–
25 minutes at 37°C. After this step, 50μL of Stop Solution was added and the plate was read at
450 nm in the spectrophotometer.
Measurements of Oxidant Stress Markers in the Plasma of Control, LVH,
Control-H2S and LVH-H2S Rats
The oxidative stress markers, superoxide dismutase (SOD) malanodialdehyde (MDA), gluta-
thione (GSH), total antioxidant capacity (T-AOC) and NO levels were measured in the plasma
by using specialised laboratory kits (NJJC Bio Inc., Nanjing, China) following the instructions
provided by the manufacturer.
Measurement of Electrocardiogram in Anesthetized Rats of Control,
LVH, Control-H2S and LVH-H2S Groups
Food was removed from the cages on the night before the experiment. The rats were anaesthe-
tised with intraperitoneal pentobarbitone sodium (60mg/kg, Nembutal1, CEVA, France).
Thereafter, a 3-lead surface ECG recording was taken using gold plated needle electrodes
(ADInstrument, Sydney, Australia) inserted underneath the skin as previously reported [42,
43]. Recordings were done for 5 minutes using an amplifier attached to a data acquisition sys-
tem (PowerLab, ADInstrument, Sydney, Australia). Data for each rat was taken as the average
of 15 electrical impulses which were then averaged for each group of rats.
Acute Experiment
After the completion of the ECG recording, the acute experiment was performed following pre-
viously reported procedures [30, 44, 45]. The trachea was exposed by a midline neck incision
and a cannula inserted to provide ease of ventilation throughout the experiment. The right
carotid artery was then cannulated (PP50, Portex, Kent, UK) and attached to a fluid-filled pres-
sure transducer (model P23 ID Gould, Statham Instruments, UK) which was connected to a
data acquisition system (PowerLab1, ADInstrument, Australia) to allow continuous monitor-
ing of mean arterial blood pressure (MAP) and heart rate (HR). The left jugular vein was can-
nulated (PP50, Portex, Kent, UK) to permit administration of maintenance doses of anesthetic
and saline infusion. A mid-line abdominal incision allowed exposure of the left kidney which
was carefully covered with a saline soaked cotton pads to prevent drying. The iliac artery was
cannulated (PP50, Portex, Kent, UK) and the cannula was attached to a second fluid-filled
pressure transducer and connected to the PowerLab system for measurement of iliac mean
blood pressure. A laser Doppler flow probe (ADInstruments, Australia) was positioned on the
outermost layer of the cortex of the left kidney to record the renal cortical blood perfusion
(RCBP). After completion of surgery, the rats were allowed to stabilize for 1 hour. The systemic
haemodynamic data, MAP and HR and the RCBP were monitored continuously for 1 hour.
The rats were euthanized at the end of the experiment with an overdose of anaesthetic. The
CSE/H2S in the Myocardium Inhibit the Progression in LVH
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pulse wave velocity (PWV) was measured by taking the propagation time from Power Lab data
while propagation distance was measured manually by putting a thread from the insertion
point of the carotid artery cannula to the insertion point of the iliac artery cannula [46, 47]. At
the end of the acute experiment, the heart was harvested, dried and weighed to allow measure-
ment of heart, LV and kidney indices. The atria, great vessels, and the right ventricle were
snipped off along its septal insertion. The LV diameter wall thickness and LV internal volume
were measured using vernier callipers as reported earlier[48].
Histopathology of LV by Using PicroSirus Red Stain Kit
Samples of LV were also taken and preserved in 10% formalin. The histopathology preparation
of the samples involved embedding, trimming and sectioning followed by staining of the heart
tissue with PicroSirus Red (Polyscience, Inc. Germany)[30]. The procedure involved the use of
three solutions, A, B and C. Firstly; the slides were dipped in solution A for 2 minutes then
rinsed well in distilled water. Then the slides were placed in solution B for 60 minutes and then
in solution C for 2 minutes. Thereafter, the slides were immersed in 70% ethanol for 45 sec-
onds. Collagen in the LV tissue will give a red colour.
Statistical Analysis
The statistical analysis for the study was undertaken using a one way analysis of variance
(ANOVA) followed by a Boneferroni post hoc test using Graph Pad Prism (Graph Pad Soft-
ware, San Diego California U.S.A) while gene expression data was analyzed by using Compara-
tive method (ΔΔCT method) StepOne™ Software, version 2.1 (Applied Biosystem, USA). All
data are presented as mean ± SEM with significance at P<0.05.
Results
Relative Quantification of CSE mRNA Expression in Myocardium,
Plasma and Tissue H2S Concentrations and CSE Activity in the Heart
It was observed that induction of LVH resulted in 3 fold decrease (CSE/β-actin mRNA ratio
0.32) in expression of CSE mRNA in the heart of the LVH as compared to the Control group
(CSE/β-actin mRNA ratio taken as 1). Exogenous administration of H2S significantly up regu-
lated (all P<0.05) the myocardial CSE mRNAs of Control-H2S and LVH-H2S when compared
to the control group cardiac CSE mRNA as shown in Fig 1A.
Plasma hydrogen sulphide (H2S) in the LVH group of rats was significantly reduced (P<0.05)
compared to H2S level in the Control group while exogenous administration of H2S significantly
increased (all P<0.05) H2S plasma levels in Control-H2S and LVH-H2S (H2S (μM); Control: 37
±1; LVH: 16±1; Control-H2S: 54±1 and LVH-H2S: 63±2) as shown in Fig 1B.
Myocardial hydrogen sulphide (H2S) levels in the LVH group of rats was significantly
reduced (P<0.05) compared to H2S level in the Control group while exogenous administration
of H2S significantly increased (all P<0.05) the myocardial H2S levels in Control-H2S and
LVH-H2S (H2S (nmol/mg of protein); Control: 31±1; LVH: 20±1; Control-H2S: 32±1 and
LVH-H2S: 29±1) as shown in Fig 1C.
CSE activity in the LVH group of rats was significantly reduced (P<0.05) compared to CSE
activity in the Control group while exogenous administration of H2S significantly increased (all
P<0.05) CSE activity in Control-H2S and LVH-H2S (CSE activity (nmol/L/g Prot/min); Con-
trol: 42±1; LVH: 23±1; Control-H2S: 66±1 and LVH-H2S: 54±1) as shown in Fig 1D.
CSE/H2S in the Myocardium Inhibit the Progression in LVH
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Plasma Concentrations of Noradrenaline and Angiotensin II
In the LVH group, plasma NA levels were significantly elevated (P<0.05) compared to the
Control group. Exogenous administration of H2S significantly reduced (P<0.05) the plasma
NA levels in the LVH-H2S compared to the LVH group (NA in plasma (pg/ml; Control:
153±3; LVH: 438±4; Control-H2S:116±2 and LVH-H2S: 283±5) and these are shown are
shown in Fig 2(A). Plasma Ang II levels were significantly elevated in the LVH (P<0.05) com-
pared to the Control group. Exogenous administration of H2S reduced plasma Ang II levels in
Fig 1. (A, B and C). Relative quantification of CSEmRNA expression in heart, concentration of H2S in the plasma and myocardium of Control, LVH, Control-
H2S and LVH-H2S. All the data is expressed as mean± SEM. * P<0.05 represents comparison with control group while # represents comparison with LVH
group.
doi:10.1371/journal.pone.0150137.g001
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the LVH-H2S less than in the LVH group (Ang II in plasma (pg/ml; Control: 304±4; LVH:
460±3; Control-H2S:250±3 and LVH-H2S: 339±3) and are shown in Fig 2(B).
Systemic Hemodynamics
The data showing the status of systemic hemodynamics in all groups is shown in Table 1. It
was observed that induction of LVH resulted in significantly elevated (P<0.05) MAP com-
pared to the Control group (Table 1). Exogenous administration of H2S significantly reduced
(P<0.05) the MAP in the LVH-H2S group when compared to that of LVH group, whilst the
Control-H2S group MAP was unchanged (MAP in mmHg: Control: 119±1; LVH: 142±5;
Control-H2S:122±6 and LVH-H2S: 122±3; Table 1)). Renal cortical blood perfusion (RCBP)
was significantly reduced (P<0.05) in LVH when compared to the Control group while exoge-
nous administration of H2S significantly increased (all P<0.06) RCBP in Control-H2S and
LVH-H2S to a level comparable to that of the Control group (RCBP in bpu; Control: 156±8;
LVH: 94±6; Control-H2S:144±3 and LVH-H2S: 134±4; Table 1). Pulse wave velocity (PWV)
was significantly reduced (P<0.05) in LVH compared to the Control group while exogenous
administration of H2S significantly increased (all P<0.06) PWV in the Control-H2S and
LVH-H2S groups to values comparable to those of the Control group (PWV in m/s; Control:
6±1; LVH: 8±1; Control-H2S:6±1 and LVH-H2S: 6±1; Table 1).
Fig 2. (A, B). Plasma concentration of noradrenaline and angiotensin II in plasma of Control, LVH, Control-H2S and LVH-H2S rat groups taken on day 35. All
the data is expressed as mean± SEM. * P<0.05 represents comparison with control group while # represents comparison with LVH group.
doi:10.1371/journal.pone.0150137.g002
Table 1. MAP, RCBP and PWV of Control, LVH, Control-H2S and LVH-H2S are shown in Table 1. All the data is expressed as mean± SEM.
Parameters Control LVH Control-H2S LVH-H2S
MAP (mmHg) 119±1 142±5* 122±6# 122±3#
RCBP (bpu) 156±8 94±6* 144±3# 134±4#
PWV (m/s) 6±1 8±1* 6±1# 6±1#
MAP: mean arterial pressure; RCBP: renal cortical blood perfusion; bpu: blood perfusion unit; PWV: pulse wave velocity and m/s: meter per second
* P<0.05 represents comparison with control group while
# P<0.05 represents comparison with LVH group.
doi:10.1371/journal.pone.0150137.t001
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Cardiac Physical Indices
All data related to cardiac physical indices are shown in Table 2. It was evident that the heart
index of the LVH group was significantly greater (P<0.05) than that of the Control group
while exogenous administration of H2S to both Control and LVH groups significantly reduced
(all P<0.05) the heart index in the LVH-H2S, but not Control-H2S group (heart index in %;
Control: 0.26±0.0; LVH: 0.38±0.0; Control-H2S: 0.27±0.0and LVH-H2S: 0.34±0.0; Table 2).
The LV index of the LVH group was significantly greater (P<0.05) than that of Control
group while exogenous administration of H2S in both Control and LVH groups significantly
reduced (P<0.05) the LV index in LVH-H2S, but not Control-H2S group (LV index in %; Con-
trol: 0.16±0.0; LVH: 0.24±0.0; Control-H2S: 0.19±0.0 and LVH-H2S: 0.21±0.0 Table 2).
The myocardial thickness in the LVH group was significantly greater (P<0.05) than that of
the Control group while exogenous administration of H2S significantly reduced (all P<0.05)
the thickness of myocardium in the LVH-H2S, but not Control-H2S (thickness of myocardium
in mm; Control: 1.6±0.0; LVH: 3.3±0.0; Control-H2S: 1.8±0.0 and LVH-H2S: 2.4±0.0; Table 2).
The internal diameter of the LV chamber of the LVH group was significantly reduced
(P<0.05) compared to that of the Control group and exogenous administration of H2S signifi-
cantly increased (all P<0.05) the internal diameter of LV chamber in the LVH-H2S but not
Control-H2S group (internal diameter of LV chamber in mm; Control: 5±0.0; LVH: 3±0.0;
Control-H2S: 4±0.2 and LVH-H2S: 5±0.0; Table 2).
Measurement of Electrocardiogram
All ECG data are shown in Table 3. The QRS complex of the LVH group was significantly
increased (P<0.05) compared to the Control group while exogenous administration of H2S
Table 2. Heart index, LV index, thickness of myocardium and internal diameter of LV chamber of Control, LVH, Control-H2S and LVH-H2S are
shown in Table 2. All the data is expressed as mean± SEM.
Parameters Control LVH Control-H2S LVH-H2S
Heart index (%) 0.26±0.0 0.38±0.0* 0.27±0.0# 0.34±0.0*#
LV index (%) 0.16±0.0 0.24±0.0* 0.19±0.0*# 0.21±0.0*#
Thickness of myocardium (mm) 1.6±0.0 3.3±0.0* 1.8±0.0*# 2.4±0.0*#
Internal diameter of LV chamber (mm) 5±0.0 3±0.0* 4±0.2*# 5±0.0#
mm: millimeter
* P<0.05 represents comparison with control group while
# P<0.05 represents comparison with LVH group.
doi:10.1371/journal.pone.0150137.t002
Table 3. QRS complex, R-R interval and R-amplitude of Control, LVH, Control-H2S and LVH-H2S. All the data is expressed as mean± SEM.
Parameters Control LVH Control-H2S LVH-H2S
QRS complex (Sec) 0.018±0.0 0.023±0.0 0.020±0.0 0.020±0.0#
R-R interval (Sec) 0.17±0.0 0.21±0.0 0.18±0.0# 0.18±0.0#
R-amplitude (mV) 0.53±0.0 0.74±0.0 0.54±0.0*# 0.63±0.0 #
Sec: second, mV: millivolts
* P<0.05 represents comparison with control group while
# P<0.05 represents comparison with LVH group.
doi:10.1371/journal.pone.0150137.t003
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resulted in a significant decrease (P<0.05) in the QRS complex (QRS complex sec; Control:
0.018±0.0; LVH: 0.023±0.0; Control-H2S: 0.020±0.0 and LVH-H2S: 0.018 ±0.0 Table 3).
The R-R interval of the LVH group significantly greater (P<0.05) when compared to the
Control group while exogenous administration of H2S resulted in significantly lower (P<0.05)
in R-R interval compared to LVH group (R-R interval sec; Control: 0.17±0.0; LVH: 0.21±0.0;
Control-H2S: 0.18±0.0 and LVH-H2S: 0.18±0.0; Table 3).
The R-amplitude in the LVH group was significantly higher (P<0.05) compared to that of
the Control group andexogenous administration of H2S resulted in a significantly lower
(P<0.05) R-amplitude compared to that of the LVH group (R-amplitude mV; Control: 0.53
±0.0; LVH: 0.74±0.0; Control-H2S: 0.54±0.0 and LVH-H2S: 0.63±0.0; Table 3).
Plasma Oxidative Stress Parameters
Plasma levels of superoxide dismutase (SOD) level in the LVH group rats was significantly
lower (P<0.05) compared to those in the Control group and were significantly increased
(all P<005) by the while exogenous administration of H2S in the LVH-H2S group (SOD
(Umol/ml); Control: 6±0.2; LVH: 3±0.7; Control-H2S: 6±0.3 and LVH-H2S: 7±0.3) as shown
in Fig 3A.
Plasma malanodialdehyde (MDA) was significantly higher (P<0.05) in the LVH group of
rats compared to those of the Control group while exogenous administration of H2S signifi-
cantly reduced (all P<0.05) MDA plasma levels in the LVH-H2S group (MDA (ɳmol/ml);
Control: 21±2; LVH: 34±1; Control-H2S: 21±1 and LVH-H2S: 23±1) as shown in Fig 3B.
Glutathione (GSH) levels in plasma of the LVH group rats was significantly lower (P<0.05)
compared to those of the Control group while exogenous administration of H2S significantly
increased (all P<0.05) the GSH plasma levels in Control-H2S and LVH-H2S (GSH (Umol/ml);
Control: 542±17; LVH: 134±19; Control-H2S: 629±37 and LVH-H2S: 731±45) as shown in
Fig 3C.
Total antioxidant capacity (T-AOC) plasma levels of the LVH group of rats was significantly
lower (P<0.05) compared to those of the Control group while exogenous administration of
H2S significantly increased (all P<0.05) the plasma T-AOC levels in the LVH-H2S group but
remained significantly (P<0.05) below that of the Control group (T-AOC (Umol/ml); Control:
18±1; LVH: 10±1; Control-H2S: 14±2 and LVH-H2S: 14±1) as shown in Fig 3D.
Plasma nitric oxide (NO) level in the LVH group of rats was significantly lower (P<0.05)
compared to the plasma NO in the Control group while exogenous administration of H2S sig-
nificantly increased (all P<0.05) the plasma NO in both Control-H2S and LVH-H2S (NO
(μmol/ml); Control: 26±1; LVH: 19±1; Control-H2S: 33±1 and LVH-H2S: 32±1) as shown in
Fig 3E.
Histopathology of LV
PicroSirius Red Staining gave a red colour to the cardiac collagen which appears as thread-
like structures. A normal amount of collagen is shown in the cardiac muscle of control rats
which provides strength to muscle (Fig 4A). In the LVH group, as shown in Fig 4B, collagen
appeared to be deposited as plaques which were present in different areas of the heart. Treat-
ment with H2S in Control group, as shown in Fig 4C, shows normal thread like branches of
collagen which are less dense than in the Control group. Exogenous administration of H2S in
LVH rats, as shown in Fig 4D, reduced the collagen plaques which were not as dense com-
pared to the LVH group. The slides show that collagen deposition in LVH is reduced after
H2S administration.
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Discussion
The present study explored the hypothesis that in left ventricular hypertrophy there would be a
down regulation of CSE mRNA in the heart with increased oxidative stress in the systemic cir-
culation.We also hypothesized that exogenous administration of H2S would up regulate cardiac
CSE associated with an attenuation of physical indices, as an antihypertophic agent on one
Fig 3. (A, B, C and D). Plasma concentration of superoxide dismutase (SOD), malanoaldehyde (MDA), glutathione (GSH) and total antioxidant capacity
(T-AOC) of Control, LVH, Control-H2S and LVH-H2S rat groups taken on day 35. All the data is expressed as mean± SEM. * P<0.05 represents comparison
with control group while # represents comparison with LVH group.
doi:10.1371/journal.pone.0150137.g003
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hand while on the other hand blunt the oxidative stress and endothelial dysfunction thereby
helping to suppress the progression of LVH. There were a number of novel observations. The
first novel observation was that the induction of LVH resulted in the down regulation of CSE
mRNA in the heart along with a corresponding decrease in H2S concentrations in the myocar-
dium and plasma. Exogenous administration of H2S not only up regulated CSE mRNA expres-
sion in the heart but also suppressed the progression of left ventricular hypertrophy associated
with a corresponding increase in H2S concentrations in the myocardium and plasma. The sec-
ond novel finding was that down regulation of CSE resulted in increased LV index, heart index
and thickness of myocardium and reduction in the internal diameter of the LV chamber. Up
regulation of the CSE mRNA/H2S pathway in the heart resulting from exogenous administra-
tion of H2S highlighted an antihypertrophic role of the CSE mRNA/H2S pathway by attenuat-
ing the heart and LV indices, reducing the thickness of the myocardium and increasing the
Fig 4. Deposition of collagen on the heart tissue of Control (A), LVH (B), Control-H2S (C) and LVH-H2S
(D) rat groups taken on day 35 by using PicroSirius Red Staining. Arrows pointing out the deposition of
collagen on myocardium in different groups.
doi:10.1371/journal.pone.0150137.g004
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internal diameter of the LV chamber. The third novel observation was that the exogenous
administration of H2S not only reduced the plasma concentrations of NA and Ang II but also
antagonized the systemic actions produced by NA and Ang II. The fourth important finding
was that the inhibition of the progression of LVH increased antioxidant mechanisms and
improved end othelial dysfunction.
The present study demonstrated that there was a down regulation of CSE mRNA in the
myocardium associated with the induction of LVH. This LVH could be due to isoproterenol as
this is known to increase cardiac hypertrophy [49]. There may be other contributory factors
causing LVH such as the elevated plasma levels of Ang II and NA in the LVH group which
may be caused by a direct action isoproterenol acting on β-adrenoceptors in the heart to
increase the force of contraction and at the kidney causing renin release from the granular cells
[49]. Both Ang II and NA are also vasoconstrictors which are probably responsible for the ele-
vated SBP and MAP in the present study. This increase in blood pressure and increased plasma
levels of Ang II and NA may be the casual factors for the reduction in CSE mRNA and CSE
activity in the heart and corresponding decrease in H2S concentrations in both plasma and
heart. This view can be supported by the report that deletion of cystathione γ lyase is associated
with the development of hypertension in mice [50] and H2S produced from CSE is known as a
vasorelaxant and blood pressure regulator [51]. Reduction in CSE activity after administration
of isoproterenol in present study is in line with the previous reported data [41].
Inhibition of CSE/H2S plays a significant role in the pathogenesis of hypertension [13] and
the activation of this pathway could be a therapeutic objective for the treatment of hyperten-
sion and LVH. We have observed an upregulation of CSE mRNA and CSE activity in the heart
and decrease in blood pressure in present study following activation of this pathway by exoge-
nous administration of H2S. It was important to realise that up regulation of CSE mRNA in the
myocardium of LVH-H2S resulted in reduced concentrations of Ang II and NA in the plasma.
This can lead to the contention that up regulation of CSE mRNA may suppress the responses
of Ang II and NA in LVH-H2S although these observations have not been made in past. The
decrease in Ang II levels may be related to angiotensin converting enzyme inhibition by H2S
[52] which would blunt Ang II production. However, the mechanisms underlying the
decreased concentration of NA by H2S is unknown however one possibility may be a negative
regulation of β-adrenergic receptors [53] by H2S which would lead to a reduction in cardiac
contractility and a consequent reduction in the work of the heart and resolution of the LVH.
This would be supported by the fact that β-blockers have been proven to be effective in causing
regression of LVH [54].The protective effect of H2S in isoproterenol induced injury of themyo-
cardium has also been reported [41]. This could arise due to the activation of potassium sensi-
tive ATP channel by H2S as activation of these channels by diazoxide has resulted in regression
of isoproterenol induced cardiac hypertrophy.[55]. We propose that the restoration of myocar-
dial geometry by H2S might be due to up regulation of CSE in the as a result of activation of
potassium sensitive ATP channels. It was evident from present study that collagen deposition
was reduced in LVH following exogenous administration of H2S. Together, these observations
would support the view that exogenous administration of H2S up regulated the CSE mRNA
and increased CSE activity in the heart, reduced the plasma concentrations of Ang II and NA
which lead to the reduction in blood pressure and inhibited the progression of LVH.
We observed in the present study that up regulation of myocardial CSE mRNA/ H2S
reduced both heart and LV indices, thickness of the myocardium and increased the internal
diameter of the LV chamber. As is evident from the present findings, plasma levels of Ang II
and NA were not only elevated but also associated with the elevated physical indices of the
heart and LV. This is consistent with previous reports that Ang II and NA are responsible for
cardiac hypertrophy [12,56, 57]. The reduction in cardiac and LV indices following exogenous
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administration of H2S indicates an antihypertrophic role of the CSE/H2S pathway which may
involve reducing the concentrations of Ang II and NA and antagonizing the growth promoting
effects of Ang II and NA. These data are in line with other studies which reported the reduction
in heart weight and heart index by H2S in the abdominal aortic coaractation (AAC) model
[12]. However the disease induction model and species difference is an important difference in
this latter study.
This attenuation in physical indices by H2S was also observed in pressure overload cardio-
myopathy model following up regulation of the CBS enzyme [26]. The present study has
emphasized the importance of the CSE enzyme which is another enzyme responsible for H2S
production in myocardium in addition to CBS. One of the possible reasons for the antihyper-
trophic role of CSE/H2S is the decreased plasma concentration of Ang II which has been
reported to be elevated in the AAC model and incriminated as a major culprit for hypertrophy
[58]. The elevated Ang II in LVH is inhibited by H2S [52]. Another possible reason may be the
vasodilator action of the H2S [59] which will reduce the after load on the heart, peripheral vas-
cular resistance and ultimately attenuation of the stretch of the ventricular walls. A diuretic
action of the H2S [60]might also be among the mechanisms leading to an unloading of the
workload on the heart via a reduction of the volume loaded stress. Together, ACE inhibitor
actions, negative regulation of β-adrenergic receptors, vasodilator and diuretic actions of the
CSE/H2S pathway will not only reduce the heart, LV indices but also will result in reduction of
the myocardium thickness and improve the internal diameter of LV chamber all of which are
evident in the present study. This becomes one of the first studies reporting an antihyper-
trophic role of H2S and in which we explored how the up regulation of CSE mRNA/H2S
promotes overcomes LVH by mitigating heart and LV indices, reducing the thickness of myo-
cardium and increasing the internal diameter of LV chamber.
Cardiac hypertrophy develops in response to many stressors [61, 62] and the production of
reactive oxygen species is evident in the findings of the present study. Oxidative stress plays a
key role in cardiac and vascular abnormalities in different types of cardiovascular diseases
which is why antioxidant therapy may be beneficial for combating these diseases [63]. So, the
elevated plasma MDA, which is an enzymatic marker of oxidative stress, together with an
attenuated level of SOD, an enzymatic marker of antioxidant activity, indicate elevated oxida-
tive stress in the LVHmodel. This shows that there is an imbalance between pro-oxidants and
antioxidant in LVH. Other antioxidant parameters, such as GSH and T-AOC are also attenu-
ated indicating a dominant role for prooxidant mechanisms in LVH. The increased levels of
Ang II may be one of the reasons underlying the increased oxidative stress [64] in the present
model of LVH. Exogenous administration of H2S resulted in the attenuation of MDA levels,
increased SOD, GSH and T-AOC in the plasma of the LVH model. These observations are in
line with many previous studies supporting an antioxidant role for H2S in LV remodelling in
different pathological conditions [65–68]. There are several reasons supporting notion and one
of the best explanations for the antioxidant action of H2S is the scavenging ability of superoxide
[67] and peroxynitrite[68]. Scavenging of these free radicals ultimately results in a reduction of
MDA and improved SOD, T-AOC and GSH levels in the plasma. Another argument for
improved antioxidant status could be due to the increased glutathione ability of H2S which
suppresses the oxidative stress [61]. Improved antioxidant capacity in the present study is evi-
dent in LVH-H2S situation which mimics the antioxidant status of the body. This finding is
similar to previous findings in lungs [69] where exogenous administration of H2S enhanced
the T-AOC content. The antioxidant contribution of H2S in causing regression of LVH is also
supported by a recently reported study [26] demonstrating up regulation of CBS in cardiomy-
opathy. Another possibility for the antioxidant action of H2S may be via its regulation of the
NO pathway. NO is antioxidant on its own and inhibits xanthine oxidase and NADPH oxidase
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and maintains the normal O2
−/NO homeostasis [70]. It is possible that following exogenous
administration of H2S restores NO plasma availability in LVH in present study. A further anti-
oxidant activity may reside in the ability of H2S to decrease the concentration of Ang II and
plasma rennin activity [71]. It can be concluded that H2S increases the antioxidant status of the
body by decreasing MDA, increasing SOD, GSH, T-AOC and NO in plasma by using its scav-
enging potential, increasing glutathione levels, regulating vascular NO and decreasing Ang II.
It became apparent that pulse wave velocity was significantly higher (33%) in the LVH
group indicating a higher endothelial dysfunction as compared to the Control group. Interest-
ingly vasoconstriction and elevated blood pressure are usually associated with greater arterial
stiffness (endothelial dysfunction) which is a predictor of cardiovascular diseases [72].
Although isoprenaline produces a peripheral vasodilation but this action may be counteracted
by an increased NA production induced by caffeine administration as observed in the present
study. These elevated levels of NA and Ang II could cause an overall vasoconstriction and
make the vasculature stiffer. Thus, the overall net effect is an increased left ventricular after-
load and greater arterial stiffness ultimately leading to endothelial dysfunction.
Treatment with H2S resulted in decreased endothelial dysfunction compared to LVH and
comparable to Control on day 35 which may be explained on the basis of multiple effects of
H2S on blood vessels. It has been reported that the vasorelaxant effect of H2S [73, 74] may be
due to its EDRF [59] and that a deficiency of H2S could ultimately lead to the pathogenesis of
arterial hypertension [75].Furthermore, the endothelial dysfunction could be ameliorated by
augmented vasorelaxation of blood vessels due to NO [76–78].
The antioxidant action of H2S may be expected to blunt the ROS degradation of NO and
increase its availability in the vascular system. An increased NO availability following H2S has
been reported earlier [73, 79]. The findings of our study are in line with these reports and is evi-
dence of increased NO production in plasma after exogenous administration of H2S. In addi-
tion to this, increased oxidative stress as a result of LVH is evident in the study and results in
vascular dysfunction [80, 81]. The Ca++ blocking ability of H2S [82] will result in vascular
smooth muscle hyper polarization causing vasorelaxation [83] and is another mechanism by
which H2S can reduce arterial stiffness. Ang II can cause arterial stiffness and ultimately LVH
[84] but the ACE inhibitor like action of H2S can prevent this increased arterial stiffness. This
could be another possible reason for H2S improving the arterial distensibility or stiffness. This
reduced arterial stiffness can be attributed to H2S and can be considered as a therapeutic moi-
ety for the regression of LVH.
Renal cortical blood perfusion (RCBP) was decreased by 36% in the LVH when compared
to Control indicating compromised blood perfusion through kidney. Exogenous administra-
tion of H2S improved the RCBP by 40% when compared to LVH. This improvement in base-
line RCBP due to exogenous administration of H2S can be explained in multiple ways. One of
the possible reason is the role of H2S as an EDRF [59]. In present LVHmodel, the vasoconstric-
tion produced by NA and Ang II are dominant factors mediating the reduced RCBP and the
EDRF action of H2S may be expected to play a counter regulatory role to minimize the vaso-
constriction in the kidney. This notion can be supported by other reports which demonstrated
that exogenous administration of H2S resulted in greater pre-glomerulus arteriolar vasodila-
tion, increased GFR and renal blood flow [38]. Local vasodilation by H2S in the kidney is likely
because of the observed elevated plasma levels of H2S which suggest that there may be an up
regulation of CSE mRNA and CSE activity throughout all tissues of the body. Another reason
for increased RCBP in LVH-H2S is the ability of H2S to increase the NO production as dis-
cussed above. Another possible reason for improved RCBP is the antioxidant potential of H2S
as decreased ROS production will reduce Ca++ influx mediated via sympathetic neurotransmis-
sion which will blunt NA secretion and consequently will result in an increase RCBP. This
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argument can be supported by an earlier report [85] which explains NA production due to
enhanced ROS production. Thus, overall, decreasing ROS generation will reduce NA and Ang
II production systemically leading to vasodilation and increases the RCBP.
Conclusion
In summary, in this isoprenaline/caffeine model of LVH there is down regulation of the CSE/
H2S pathway in the heart with increased oxidative stress in the systemic circulation. Exogenous
administration of H2S up regulated the cardiac CSE/ H2S pathway resulting in an attenuation
of the increased LV index, heart index and thickness of the myocardium. This CSE/H2S path-
way on one hand antagonizes the hypertrophic actions of angiotensin II and noradrenaline
while on the other hand H2S attenuates the oxidative stress, endothelial dysfunction which
together help to suppress the progression of LVH. Exogenous administration of H2S aug-
mented the reduced renal cortical blood perfusion in LVH state.
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